Olatorepatide Drug Asset Due Diligence Report 2026

This Olatorepatide Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 24 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

NDA/BLA

Highest phase

Registered trials

Result records

Matched deals

Executive recommendation: GO

Decision memo

Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.

The central underwriting question is whether Olatorepatide can convert its Synthetic peptide profile and GIPR x GLP-1R biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	Olatorepatide (query alias: Olatorepatide)
Modality / target	Synthetic peptide; GIPR x GLP-1R; GIPR agonists, GLP-1R agonists
Highest global status	NDA/BLA
Originator	Hansoh Pharmaceutical Group Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Co., Ltd.
Active developers	Regeneron Pharmaceuticals, Inc., Jiangsu Hansoh Pharmaceutical Group Co., Ltd.

The MCP disease footprint includes Obesity, Diabetes Mellitus, Type 2, Prediabetic State. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
NCT07156500	Phase 3	Not yet recruiting	204	Change in HbA1c
NCT07685808	Phase 2	Not yet recruiting	360	Occurrence of Treatment-Emergent Adverse Events (TEAEs)
NCT07431086	Phase 2	Active, not recruiting	120	Occurrence of Treatment-Emergent Adverse Events (TEAEs)

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

翰森制药｜奥莱泊肽（HS-20094）在 III 期研究中实现48周平均体重降幅最高达 19.3%，且胃肠道耐受性显著改善

临床3期; n=604; evaluation: 积极. Reported fields: - 达到; 体重(48周) = -19.3 % 达到

Efficacy and Safety of HS-20094 in Patients with Type 2 Diabetes—A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Trial

Phase 2; n=54; evaluation: Positive. Reported fields: AE = The occurrence of adverse events (AEs) was not dose-dependent in HS-20094. The most common AE included decreased appetite, abdominal distension and vomiting. No severe hypoglycemia was reported. ; AE = The occurrence of adverse events (AEs) was not dose-dependent in HS-20094. The most common AE included decreased appetite, abdominal distension and vomiting. No severe hypoglycemia was reported. ; AE = The occurrence of adverse events (AEs) was not dose-dependent in HS-20094. The most common AE included decreased appetite, abdominal distension and vomiting. No severe hypoglycemia was reported.

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

Olatorepatide addresses Obesity, Diabetes Mellitus, Type 2, Prediabetic State. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Synthetic peptide—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The strongest market-validation signal in this screen is partner behavior: 1 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.

5. Transaction precedent and economics

Date	Transaction	Phase at deal	Disclosed economics
2025-06-02	Regeneron Expands Clinical-Stage Obesity Portfolio with Strategic In-Licensing of Novel Dual GLP-1/GIP Receptor Agonist	Phase 3	US$80.0M upfront; US$1,930.0M milestones

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

The milestone feed surfaced a patent-application signal described as “Combination of GLP-1r/GIPR dual agonist and FGF21 compound and use”.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.

7. Principal risks and diligence gates

Class crowding and differentiation versus other PD-(L)1/VEGF agents
Immune and anti-angiogenic safety, including bleeding and cardiovascular risk
Biomarker strategy, indication selection, and head-to-head endpoint execution

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

GO